Skip to main content
Premium Trial:

Request an Annual Quote

Big Pharma's Got One Toe In, At Least

At VentureBeat, David Hamilton points to news reported in the New York Times of the establishment of the International Serious Adverse Events Consortium. The consortium consists of seven big pharma companies, each of which will contribute funds to research into developing genetic tests to determine which patients are at risk from dangerous drug side effects. According to Hamilton, it’s good that “one of the first major industry-wide personalized medicine efforts should focus specifically on rare side effects, since it is exactly these sorts of safety problems that pose the biggest threat to the blockbuster-drug model in the first place.” However, he’s not sure if this means that big pharma is ready to buy into personalized medicine wholesale.


The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.